Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year overall
survival of 11%. The disease is usually diagnosed at advanced stages, and systemic
chemotherapy is the standard-of-care treatment for the majority of patients with PDAC.
Although novel treatment options, such as targeted therapy and immunotherapy, have
achieved substantial progress leading to practice-changing results, with FDA approvals
for several solid tumors so far, the progress achieved for PDAC is relatively limited.
Recent studies uncovered potential therapeutic targets for patients with PDAC, and
potential therapeutic opportunities are currently being further examined. Herein,
we review recent advances in systemic therapy regimens, including cytotoxic agents,
targeted therapies, immunotherapy, and novel therapeutic options for managing patients
with PDAC. We also elaborate on molecular profiling to guide treatment and existing
therapeutic opportunities that may further advance the clinical care of patients with
this devastating disease.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics.CA Cancer J Clin. 2022; 72: 7-33
- Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.Cancer Med. 2016; 5: 2649-2656
- Pancreatic cancer.Lancet North Am Ed. 2016; 388: 73-85
- Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Expert Opin Ther Targets. 2016; 20: 341-359
- Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?.Ann Oncol. 2017; 28: 2950-2961
- SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.Clin Cancer Res. 2009; 15: 4674-4679
- Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.Yonsei Med J. 2005; 46: 519-525
- Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations.Clin Cancer Res. 2018; 24: 1326-1336
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med. 2011; 364: 1817-1825
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med. 2013; 369: 1691-1703
- Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.BMC Cancer. 2021; 21: 537
- From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.Nat Rev Clin Oncol. 2020; 17: 108-123
- A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.Therap Adv Med Oncol. 2017; 9: 75-82
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.Br J Cancer. 2020; 122: 333-339
- A randomized, multicenter, phase II trial of gemcitabine (G) , cisplatin (C)+/-veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g) BRCA/PALB2 mutation.Am Soc Clin Oncol. 2020;
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.Lancet North Am Ed. 2016; 387: 545-557
- Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.BMC Cancer. 2018; 18: 1-10
- FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.BMC Cancer. 2014; 14: 1-8
- Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.Cancer Discov. 2018; 8: 1096-1111
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.Lancet Oncol. 2020; 21: 508-518
- Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.Expert Rev Gastroenterol Hhepatol. 2016; 10: 893-905
- Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program.JCO Precis Oncol. 2019; 3: 1-10
- Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selectiongenomic methods identify HRD and benefit to platinum in PDAC.Clin Cancer Res. 2020; 26: 3239-3247
- Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation.J Clin Oncol. 2020; 38: 1378
- Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?.J Gastrointest Oncol. 2016; 7: 738
- Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.N Engl J Med. 2019; 381: 317-327
- Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2.J Clin Oncol. 2021; 39: 2497-2505
- The NCCN 2022 annual conference.J Natil Comprehensive Cancer Network. 2022; 20: 549-550
- Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.Lancet Oncol. 2022; 23: 1009-1020
- Sotorasib for lung cancers with KRAS p.G12C mutation.N Engl J Med. 2021; 384: 2371-2381
- KRAS: the critical driver and therapeutic target for pancreatic cancer.Cold Spring Harb Perspect Med. 2018; 8
- KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.J Exp Clin Cancer Res. 2020; 39: 227
- Pancreatic cancer genomes: implications for clinical management and therapeutic development.Clin Cancer Res. 2017; 23: 1638-1646
- First Data for Sotorasib in Patients With Pancreatic Cancer With KRAS P. G12C Mutation: A Phase I/II Study Evaluating Efficacy And Safety.American Society of Clinical Oncology, 2022
- KRYSTAL-1: Updated Activity and Safety of Adagrasib (MRTX849) in Patients (Pts) With Unresectable or Metastatic Pancreatic Cancer (PDAC) and Other Gastrointestinal (GI) Tumors Harboring A KRASG12C Mutation.American Society of Clinical Oncology, 2022
- Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.J Clin Oncol. 2022; 40 (591-591)
- A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.J Clin Oncol. 2020; 38: TPS3651
Christensen JG. Discovery and characterization of MRTX1133, a selective non-covalent inhibitor of KRASG12D. Paper presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics: Virtual; 2021.
- First-In-Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)-Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors.Journal of Clinical Oncology. 2022; 40: TPS2701
- Neoantigen T-cell receptor gene therapy in pancreatic cancer.N Engl J Med. 2022; 386: 2112-2119
- Expanding the reach of precision oncology by drugging All KRAS mutants.Cancer Discov. 2022; 12: 924-937
- Novel ALK fusion, PPFIBP1-ALK, in pancreatic ductal adenocarcinoma responsive to alectinib and lorlatinib.JCO Precision Oncology. 2020; 4: 865-870
- Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma.Clin Cancer Res. 2022; 28: 2704-2714
- Identification of targetable gene fusions and structural rearrangements to foster precision medicine in KRAS wild-type pancreatic cancer.JCO Precision Oncology. 2021; 5: 65-74
- RAF1 rearrangements are common in pancreatic acinar cell carcinomas.Mod Pathol. 2020; 33: 1811-1821
- MEK inhibitor therapy in carcinomas with RAF1 fusions: inferior response in a patient with pancreatic acinar cell carcinoma.JCO Precision Onco. 2019; 3: 1-2
- A novel agnostic tumor: NTRKoma.J Oncol Pharm Pract. 2021; 27: 802-803
- Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic Cancer Who Harbor NTRK and ROS1 Fusions.American Society of Clinical Oncology, 2018
- NRG1 fusions in KRAS wild-type pancreatic cancerNRG1 fusions in KRAS wild-type pancreatic cancer.Cancer Discov. 2018; 8: 1087-1095
- Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangementsTargeting cancers with NRG1 rearrangements.Cancer Discov. 2022; 12: 1233-1247
- Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.Gut. 2021; 70: 148-156
- Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1431-1438
- Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1431-1438
- LBA65 The Canadian Cancer Trials Group PA. 7 trial:rResults of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).Ann Oncol. 2020; 31: S1195
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).Journal of Clinical Oncology. 2020; 38: 4540
- Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.Nat Cancer. 2021; 2: 1124-1135
- Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.J Hematol Oncol. 2021; 14: 1-21
- Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer.Front Oncol. 2018; 8: 370
- Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.Acta Biomater. 2019; 90: 300-313
- Phase 2 Trial of the IDO Pathway Inhibitor Indoximod Plus Gemcitabine/Nab-Paclitaxel for the Treatment of Patients With Metastatic Pancreas Cancer.American Society of Clinical Oncology, 2018
- A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.Cancer Med. 2019; 8: 5148-5157
- Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).Journal of Clinical Oncology. 2019; 37: 369
- The next wave of stroma-targeting therapy in pancreatic cancer.Cancer Res. 2019; 79: 328-330
- Pancreatic cancer microenvironment: a current dilemma.Clin Transl Med. 2019; 8
- Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer.J Clin Oncol. 2015; 33: 1-8
- Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer.Infin Pharm. 2012;
- Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313.J Clin Oncol. 2019; 37: 1062
- HALO 109-301: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Pegvorhyaluronidase Alfa (PEGPH20)+ Nab-Paclitaxel/Gemcitabine (AG) in Patients (pts) With Previously Untreated Hyaluronan (HA)-High Metastatic Pancreatic Ductal Adenocarcinoma (mPDA).American Society of Clinical Oncology, 2020
- Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.BMC Cancer. 2021; 21: 1-11
- Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?.Ann Oncol. 2017; 28: 2950-2961
- Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.Br J Cancer. 2019; 121: 809-818
- Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.Oncogene. 2022; 41: 3640-3654
- KRAS mutation dictates the cancer immune environment in pancreatic ductal adenocarcinoma and other adenocarcinomas.Cancers. 2021; 13: 2429
- The TGF-β/Smad4 signaling pathway in pancreatic carcinogenesis and its clinical significance.J Clin Med. 2017; 6: 5
- Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models.Oncoimmunology. 2019; 8e1539613
- Phase II, Open-Label, Randomized Study of First-Line Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel (GN) in Claudin 18.2–Positive Metastatic Pancreatic Cancer (mPC).American Society of Clinical Oncology, 2020
Article info
Publication history
Published online: November 04, 2022
Accepted:
November 1,
2022
Received in revised form:
October 1,
2022
Received:
July 10,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
